Adjuvant therapy of malignant melanoma: is there a choice?
- 30 November 2001
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 40 (2), 187-193
- https://doi.org/10.1016/s1040-8428(01)00099-3
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190Journal of Clinical Oncology, 2000
- A new American Joint Committee on Cancer staging system for cutaneous melanomaCancer, 2000
- Multi-Institutional Melanoma Lymphatic Mapping Experience: The Prognostic Value of Sentinel Lymph Node Status in 612 Stage I or II Melanoma PatientsJournal of Clinical Oncology, 1999
- Adjuvant therapy of melanomaThe Lancet, 1998
- 7 Adjuvant therapy of malignant melanoma; the unreachable goal?Melanoma Research, 1997
- 2nd International Conference on the AdjuvantTherapy of Malignant Melanoma London, UK, 14–15 March, 1997Melanoma Research, 1997
- Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.Journal of Clinical Oncology, 1996
- 18 Preoperative chemotherapy with cisplatin, vinblastine and dacarbazine (CVD) in patients with local-regional recurrence of melanoma (AJCC stage-HI)Melanoma Research, 1995
- Results of adjuvant interferon study In WHO melanoma programmeThe Lancet, 1994
- A Multifactorial Analysis of MelanomaAnnals of Surgery, 1981